Flavonoid Isoquercitrin Fights Atherosclerosis Through Gut Microbiome Axis
Isoquercitrin reshapes gut bacteria and tryptophan metabolism to reduce arterial plaque, pointing to a novel gut-heart therapeutic pathway.
Summary
Researchers investigated how isoquercitrin, a natural flavonoid found in many plants and foods, combats atherosclerosis. The study found that isoquercitrin reduced arterial plaque buildup and improved cholesterol profiles in animal models. Crucially, it worked by reshaping the gut microbiome — boosting beneficial bacteria like Lactobacillus — which then converted the compound into active metabolites. These bacteria also shifted tryptophan metabolism away from the inflammatory kynurenine pathway toward protective indole compounds, strengthening the intestinal barrier. Network pharmacology analysis identified HSP90β as a likely molecular target for isoquercitrin and its metabolites. The findings reveal a gut microbiota–tryptophan metabolism–HSP90β axis as a novel mechanism linking a dietary flavonoid to cardiovascular protection, suggesting real potential for food-based or supplemental interventions against heart disease.
Detailed Summary
Atherosclerosis remains a leading cause of cardiovascular death worldwide, and emerging research increasingly implicates the gut microbiome as a key player alongside traditional risk factors like lipid levels and inflammation. Understanding how natural dietary compounds interact with gut bacteria to influence cardiovascular disease opens new doors for prevention and treatment.
This study examined isoquercitrin (ISO), a flavonoid glycoside abundant in foods like onions, buckwheat, and various medicinal plants. Researchers administered ISO to atherosclerosis-prone animal models and used a combination of microbiome analysis, metabolomics, network pharmacology, and molecular docking to map its mechanisms of action.
ISO administration significantly reduced atherosclerotic plaque burden and improved lipid profiles. It also restored gut microbial balance by enriching beneficial taxa including Lactobacillus, Dubosiella, and Eubacterium_R. These bacteria expressed β-glucosidase enzymes that converted ISO into bioactive metabolites such as cis-dihydroquercetin and 3,4-DHPPAL. Simultaneously, ISO reprogrammed tryptophan metabolism — boosting protective indole derivatives while suppressing the pro-inflammatory kynurenine pathway — which strengthened intestinal barrier integrity. Network pharmacology and molecular docking identified HSP90β as a plausible host target for ISO and its metabolites quercetin and cis-dihydroquercetin, with correlation analysis linking HSP90β expression to key tryptophan pathway enzymes.
These findings suggest a coherent gut microbiota–tryptophan metabolism–HSP90β regulatory axis through which a common dietary flavonoid exerts cardiovascular protection. This multi-pathway mechanism highlights how food-derived compounds can leverage the microbiome to generate therapeutic effects beyond their direct pharmacological actions.
Important caveats apply. This study was conducted in animal models, and human translation remains unconfirmed. The summary is based on the abstract only, so methodological details, sample sizes, and full statistical analyses could not be evaluated. Clinical trials will be needed before any therapeutic recommendations can be made.
Key Findings
- Isoquercitrin significantly reduced arterial plaque burden and improved lipid profiles in atherosclerosis models.
- ISO enriched beneficial gut bacteria (Lactobacillus, Dubosiella) that convert it into bioactive metabolites.
- ISO shifted tryptophan metabolism toward protective indole compounds, suppressing the inflammatory kynurenine pathway.
- HSP90β identified as a likely molecular target for isoquercitrin and its gut-derived metabolites.
- A gut microbiota–tryptophan–HSP90β axis may explain how dietary flavonoids protect against heart disease.
Methodology
The study used atherosclerosis animal models treated with isoquercitrin, combining gut microbiome sequencing, metabolomics, network pharmacology, and molecular docking. Correlation analyses linked microbial taxa to metabolic pathway changes and host protein targets. Full methodological details, including sample sizes and statistical thresholds, were not available from the abstract alone.
Study Limitations
This research was conducted in animal models, and results may not directly translate to human cardiovascular disease. The summary is based on the abstract only, so full methodology, sample sizes, and statistical rigor could not be assessed. Network pharmacology and molecular docking findings are computational and require experimental validation in human systems.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.